2025-12-13 - Analysis Report
Here's a comprehensive analysis of Teladoc Health Inc. (TDOC) based on the provided data.

**0) Report Structure:**

The report will present the data first, followed by analysis.

**1) Return Rate Comparison:**

*   **Ticker:** TDOC
*   **Company Name:** Teladoc Health Inc.
*   **Company Overview:** A virtual healthcare company offering telehealth services.
*   **TDOC Cumulative Return:** -61.93%
*   **VOO (S&P 500) Cumulative Return:** 103.41%
*   **Divergence:**
    *   Current: -165.1
    *   Relative Divergence: 0.3 (Near the bottom of its historical range)

**Analysis:** TDOC has significantly underperformed the S&P 500 (VOO) over the analyzed period. The current divergence is substantial, indicating a large difference in cumulative returns. The relative divergence of 0.3 suggests TDOC's underperformance is near the lower end of its historical underperformance range compared to the S&P 500.

**Alpha, Beta Analysis Table:**

| Year       | CAGR    | MDD   | Alpha   | Beta   | Cap(B) |
|------------|---------|-------|---------|--------|--------|
| 2015-2017  | 77.0%   | 70.4% | 51.0%   | -0.1   | 6.1    |
| 2016-2018  | 101.0%  | 69.4% | 86.0%   | -0.1   | 8.6    |
| 2017-2019  | 141.0%  | 73.8% | 118.0%  | 0.3    | 14.6   |
| 2018-2020  | 105.0%  | 80.9% | 81.0%   | 0.3    | 34.8   |
| 2019-2021  | -78.0%  | 80.9% | -125.0% | 0.3    | 16.0   |
| 2020-2022  | -252.0% | 85.9% | -251.0% | -0.9   | 4.1    |
| 2021-2023  | -315.0% | 85.9% | -316.0% | -1.8   | 3.8    |
| 2022-2024  | -93.0%  | 85.9% | -113.0% | -1.9   | 1.6    |
| 2023-2025  | -33.0%  | 81.6% | -100.0% | -0.8   | 1.3    |

**Analysis:** The table shows a dramatic shift in Teladoc's performance. From 2015-2020, TDOC experienced very high growth (CAGR) and positive alpha (outperformance). However, since 2019, the company has experienced significant losses with very negative Alpha. Also, Beta is recently negative, which means the stock is moving in the opposite direction of the market. The market capitalization also decreased drastically, which mean investors confidence dramatically dropped.

**2) Recent Stock Price Fluctuations:**

*   **Current Close:** 7.69
*   **Last Market Data:** Price: 7.55, Previous Close: 7.62, Change: -0.92%
*   **5-day SMA:** 7.664
*   **20-day SMA:** 7.326
*   **60-day SMA:** 8.0145

**Analysis:** The stock price is currently fluctuating around its 5-day moving average and is above its 20-day moving average. However, the price is under 60-day moving average, which indicate the stock is in the down trend. The recent small price decrease indicates a minor downward pressure.

**3) Index Analysis:**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 65.99 (Approaching overbought)
*   **PPO:** 1.13 (Positive trend)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (134 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** -0.2 (Short-term decline)
*   **Expected Return (%):** -10167.3 (Very Negative)

**Analysis:** The MRI suggests a medium level of investment risk. The RSI is approaching overbought, which can mean the stock is going to be overvalued. PPO suggests a positive trend, but the negative change in relative divergence in the last 20 days and the extremely negative expected return raises strong concerns about TDOC's near-term and long-term investment potential. Hybrid Signal shows positive sign, however, the expected return doesn't correspond with the sign.

**4) Recent News & Significant Events:**

*   **Teladoc Health (TDOC): Assessing Valuation After Recent Short-Term Share Price Rebound**
*   **Teladoc Amends Incentive Plan to Increase Shares**
*   **Will Barclays’ Equal-Weight Initiation Reframe Teladoc’s (TDOC) Virtual Care Risk‑Reward Narrative?**
*   **Is Teladoc Stock a Buy After Oracle Investment Management Upped Its Stake?**
*   **Barclays Initiates Coverage of Teladoc Health (TDOC) with Equal-Weight Recommendation**
*   **Teladoc Health (TDOC): Reassessing Valuation After Barclays’ Fresh Coverage Sparks Investor Debate**

**Analysis:** The news headlines are mixed. There's a focus on valuation assessments, analyst initiations with neutral ("Equal-Weight") ratings, and debate surrounding the company's risk-reward profile. Oracle's increased stake is a positive signal, but the overall tone suggests uncertainty about TDOC's future performance.

**4-2) Analyst Opinions:**

*   **Consensus:** Hold
*   **Mean:** 2.67 (~Hold)
*   **Opinions:** 22
*   **Target Price (avg/high/low):** 9.18 / 12.00 / 7.00

**Analysis:** Analyst consensus is "Hold," indicating a neutral outlook. The average target price of $9.18 suggests a potential upside from the current price, but there's significant variability in the high and low target prices, reflecting differing opinions on the stock's prospects. No recent rating changes are provided.

**5) Recent Earnings Analysis:**

| 날짜       | EPS   | 매출     |
|------------|-------|----------|
| 2025-10-30 | -0.28 | 0.63 B$  |
| 2025-07-30 | -0.19 | 0.63 B$  |
| 2025-05-01 | -0.53 | 0.63 B$  |
| 2024-10-31 | -0.19 | 0.64 B$  |
| 2025-10-30 | -0.19 | 0.64 B$ |

**Analysis:** Teladoc has consistently reported negative EPS (Earnings Per Share) over the past few quarters, indicating a lack of profitability. Revenue has remained relatively stable around $0.63-0.64 billion, but hasn't translated into positive earnings.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-09-30 | $0.63B | 70.12%         |
| 2025-06-30 | $0.63B | 69.85%         |
| 2025-03-31 | $0.63B | 68.73%         |
| 2024-12-31 | $0.64B | 70.50%         |
| 2024-09-30 | $0.64B | 71.94%         |

**Capital and Profitability:**

| Quarter      | Equity  | ROE      |
|--------------|---------|----------|
| 2025-09-30 | $1.39B | -3.56%    |
| 2025-06-30 | $1.42B | -2.30%    |
| 2025-03-31 | $1.43B | -6.52%    |
| 2024-12-31 | $1.49B | -3.25%    |
| 2024-09-30 | $1.51B | -2.21%    |

**Analysis:** Revenue is relatively stable, and Profit Margin is consistently around 70%, showing good operational efficiency. However, the negative Return on Equity (ROE) confirms that the company is not generating profits for its shareholders. Equity is also decreasing, showing negative sign.

**7) Comprehensive Analysis (Summary):**

Teladoc Health (TDOC) presents a mixed picture.

*   **Negative Performance:** The stock has significantly underperformed the S&P 500, with a large negative divergence.
*   **Declining Trend:** TDOC has experienced very high growth from 2015 to 2020, but there have been significant losses since 2019.
*   **Mixed Signals:** Recent stock price movements show a slight downward trend. The Market Risk Indicator is at a medium level, but the RSI is approaching overbought.
*   **Uncertain Outlook:** Analyst opinions are neutral ("Hold"), and news headlines indicate concerns about valuation and risk-reward.
*   **Unprofitable:** The company consistently reports negative EPS and ROE, despite stable revenue and high profit margins.
*   **Concerning Outlook:** The negative expected return indicates a concerning outlook for the stock in the future.

**Overall Conclusion:** Based on the data, Teladoc Health (TDOC) currently appears to be a risky investment. The negative profitability, significant underperformance, and uncertain outlook suggest caution. A potential investor should conduct further research and consider the high level of risk before investing in TDOC.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.